Source: Virtual Congress 2020 – Respiratory viruses in the "pre COVID-19" era
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Gumeniuk (Kyiv, Ukraine), M. Gumeniuk (Kyiv, Ukraine), I. Dziublik (Kyiv, Ukraine), S. Fadeeva (Kyiv, Ukraine), S. Opimakh (Kyiv, Ukraine), O. Denysov (Kyiv, Ukraine). The efficacy of the decamethoxin against simple and complex viruses. 2388

Member's Comments

No comment yet.

Related content which might interest you: Protective efficacy of virus like particles (VLPs) containing the influenza HA and/or NA in a murine model of postinfluenza bacterial pneumonia Source: Virtual Congress 2020 – Translational science in respiratory infections Year: 2020 The results of a randomized clinical trial of the efficacy of the antibodies-based drug in influenza and acute respiratory viral infections in children Source: International Congress 2019 – New insights into childhood infections: from viral bronchiolitis to bronchiolitis obliterans Year: 2019 Protective efficacy and antigenicity of influenza HA-VLPs in a murine model of postinfluenza bacterial pneumonia. Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019 The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021 New treatments for RSV and other viruses, including update on vaccines Source: ERS Courses: Paediatric respiratory infections Year: 2019 The efficacy and safety of new combined medicinal product in the treatment of influenza: The results of a multicenter randomized comparative clinical trial Source: Annual Congress 2013 –Viral infections: what is new? Year: 2013 Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19 Source: Eur Respir J, 55 (6) 2000858; 10.1183/13993003.00858-2020 Year: 2020 Inhibition by umifenovir is broadly effective against coronaviruses Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021 Method of evaluation of tuberculocidal effectiveness of disinfectants in clinical strains of Mycobacterium tuberculosis Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010 Efficacy of the neuraminidase inhibitors in treating influenza pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 186s Year: 2004 Potential synergism of drugs with anti-viral and pulmonary oedema clearance activity may be advantageous for influenza patients Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections Year: 2011 Immunogenicity and safety of a novel recombinant pandemic influenza vaccine containing a polysaccharide adjuvant Source: Annual Congress 2010 - Influenza A (H1N1) and other viral infections: therapeutic aspects Year: 2010 Bioresorbable polymer structures - promising carriers for prolonged forms of anti-tuberculosis drugs Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 A randomised controlled trial comparing the immunogenicity, safety and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a needless injector device versus a traditional pre-filled syringe and needle Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Comparison of the efficacy and safety of 5 different doses of the novel very long acting β2-agonist carmoterol Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 The case for assessing the full value of new tuberculosis vaccines Source: Eur Respir J, 55 (3) 1902414; 10.1183/13993003.02414-2019 Year: 2020